Meds & supplements › Mirabegron
Medicine · beta3-Adrenergic Agonist
Mirabegron extended-release tablets are beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗
It is not known if mirabegron extended-release tablets are safe and effective in children under 3 years of age.
Mirabegron extended-release tablets may cause serious side effects, including:
Adults with Overactive Bladder
The most common side effects of mirabegron extended-release tablets include:
Tell your doctor if you have any side effect that bothers you, does not go away, or if you have swelling of the face, lips, tongue or throat, hives, skin rash or itching while taking mirabegron extended-release tablets.
These are not all the possible side effects of mirabegron extended-release tablets. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088 or Lupin Pharmaceuticals, Inc. at 1-800-399-2561.
Do not take mirabegron extended-release tablets if you are allergic to mirabegron or any of the ingredients in mirabegron extended-release tablets. See the end of this Patient Information leaflet for a complete list of ingredients in mirabegron extended-release tablets.
Before you take mirabegron extended-release tablets, tell your doctor about all of your medical conditions, including if you:
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Mirabegron extended-release tablets may affect the way other medicines work, and other medicines may affect how mirabegron extended-release tablets work.
Especially tell your doctor if you take:
Keep mirabegron extended-release tablets and all medicines out of the reach of children.
General information about the safe and effective use of mirabegron extended-release tablets.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use mirabegron extended-release tablets for a condition for which it was not prescribed.
Do not give mirabegron extended-release tablets to other people, even if they have the same symptoms you have. It may harm them.
This leaflet summarizes the most important information about mirabegron extended-release tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about mirabegron extended-release tablets that is written for health professionals.
sofidex [Internet]. Daloreum; c2026. Mirabegron; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/mirabegron
sofidex. (2026, August 3). Mirabegron. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/mirabegron
Mirabegron. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/mirabegron
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.